Business, energy, technology, markets and global industry news from Business News Today

Merck KGaA

PharmaDeviceNews Merck KGaA
Infographic highlighting Bio-Techne shareholder approval of Merck KGaA’s $11.3 billion cash acquisition and its focus on multi-omics, diagnostics and cell therapy.
Pharma & Biotech

Merck KGaA’s $11.3bn Bio-Techne deal clears shareholder vote as life-science tools consolidation advances

Bio-Techne shareholders have approved Merck KGaA’s $11.3 billion cash acquisition, clearing a major hurdle in a transaction designed to expand the German group across multi-omics, spatial biology, precision diagnostics and cell therapy workflows.

Read More
Medical Devices & Diagnostics Pharma & Biotech

Merck KGaA just made a quiet digital-health move. Could hybrid drugs be pharma’s next big reset?

Digital therapeutics struggled alone. Remepy and Merck KGaA are testing whether software works better when built into the drug itself.

Read More
Representative image of a knee joint affected by tenosynovial giant cell tumor (TGCT), the rare condition targeted by pimicotinib, now under FDA review for potential approval as a first-in-class oral CSF-1R inhibitor.
Pharma & Biotech

FDA accepts pimicotinib NDA for TGCT: What this signals for rare tumor drug development and the CSF-1R inhibitor class

Find out how Abbisko’s TGCT drug pimicotinib just crossed a major milestone with the FDA—and what this means for patients and the CSF-1R class.

Read More